RxDoctor Payments Data

Robert Staton, MD

Psychiatry · Fargo, NDNPI 1457398711

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 24.8% of the total.

$648in general payments, 2019–2025

Across 40 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$161
  • Lundbeck LLC$92
  • Teva Pharmaceuticals USA, Inc.$90
  • Alkermes, Inc.$87
  • Neurocrine Biosciences, Inc.$51
  • Takeda Pharmaceuticals U.S.A., Inc.$39
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$648 in reported general payments places this provider in the 80th percentile of 63 psychiatry providers in North Dakota.

See all psychiatry providers in North Dakota

Medicare billing

Part B allowed, 2024
$23,425
Medicare patients
65
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl63$87,387
Abilify MaintenaAripiprazole24$49,711
FanaptIloperidone14$24,483
VyvanseLisdexamfetamine Dimesylate69$23,469
VivitrolNaltrexone Microspheres12$19,723
Lurasidone Hcl59$17,904
Lisdexamfetamine Dimesylate70$14,584
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine514$10,611
Chlorpromazine Hcl75$6,223
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine102$4,786
Bupropion XlBupropion Hcl255$3,703
Carbamazepine ErCarbamazepine36$3,380
Methylphenidate ErMethylphenidate Hcl38$3,306
Divalproex Sodium ErDivalproex Sodium55$3,092
Trazodone Hcl169$2,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$161$87,38763 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$39$23,46969 claims
Alkermes, Inc.Vivitrol$87$19,72312 claims
Teva Pharmaceuticals USA, Inc.Loxapine$90$60022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 63 psychiatry providers in North Dakota.

Other psychiatry in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →